GlassScriptPhysician profile
Alexandra Palgon
NPI 1518262450
$5,154.48
in general payments reported to CMS, 2019-2025
26 companies · $1,040 in 2025
The $1,040 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $275 · 2022: $882 · 2023: $1,025 · 2024: $1,933 · 2025: $1,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,998.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,997.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,102.47 | 2021-2025 | |
| Leo Pharma INC. | $708.25 | 2022-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $433.53 | 2021-2025 | Dupixent |
| Pfizer INC. | $302.42 | 2022-2025 | |
| Galderma Laboratories, L.P. | $277.27 | 2022-2025 | Nemluvio, Aklief |
| Incyte Corporation | $265.78 | 2023-2025 | Opzelura |
| Genzyme Corporation | $246.98 | 2022-2025 | |
| Lilly USA, LLC | $226.56 | 2024-2025 | Ebglyss, Taltz |
| E.R. Squibb & Sons, L.L.C. | $214.90 | 2022-2024 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.02 | 2023-2025 | Spevigo |
| Amgen INC. | $167.55 | 2021-2025 | Otezla, Enbrel |
| Ucb, INC. | $147.11 | 2024 | Bimzelx |
| Janssen Biotech, INC. | $143.44 | 2022-2024 | Tremfya, Remicade, Simponi |
| Mayne Pharma Commercial LLC | $126.30 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $117.20 | 2022-2024 | Winlevi, Ilumya |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $101.25 | 2024-2025 | Seysara |
| Arcutis Biotherapeutics, INC. | $87.41 | 2023-2024 | Zoryve |
| Dermavant Sciences, INC. | $62.90 | 2023-2024 | Vtama |
| Verrica Pharmaceuticals INC. | $41.54 | 2024-2025 | Ycanth |
| Epi Health, LLC | $36.72 | 2021-2022 | |
| Journey Medical Corporation | $35.15 | 2025 | |
| Novartis Pharmaceuticals Corporation | $35.14 | 2024-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.90 | 2023 | Targretin, Siliq |
| Botanix Sb INC | $17.71 | 2025 | Sofdra |
| Merz North America, INC. | $17.06 | 2021 | |
| Hydrofera LLC | $14.92 | 2024 | Hydrofera Blue |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Palgon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.